Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo

Neuroscience Letters

Volumn 474, Issue 2, 2010, Pages 99-103

  Zhang, Hong Ning ^a,b   An, Chun Na ^a,b   Zhang, Hui Nan ^a,b   Pu, Xiao Ping ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

In vivo; MPTP; Neuroprotection; Parkinson's disease; Protocatechuic acid

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; DOPAMINE; PROTOCATECHUIC ACID; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; HISTOPATHOLOGY; IN VIVO STUDY; LATENT PERIOD; MALE; METABOLITE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SUBSTANTIA NIGRA; UPREGULATION;

ANIMALS; ANTIOXIDANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; HOMOVANILLIC ACID; HYDROXYBENZOIC ACIDS; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; ROTAROD PERFORMANCE TEST; TYROSINE 3-MONOOXYGENASE;

EID: 77951207425     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.03.016     Document Type: Article

References (24)

1. +-induced neurotoxicity in PC12 cells. Food Chem. Toxicol. 2006, 44:436-443.
2. Banerjee R., Starkov A.A., Beal M.F., Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 2009, 1792:651-663.
3. Cheng Y.X., He G.R., Mu X., Zhang T.T., Li X.X., Hu J.J., Xu B., Du G.H. Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile. Neurosci. Lett. 2008, 441:16-20.
4. Chiba K., Trevor A., Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 1984, 120:574-578.
5. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979, 1:249-254.
6. Geng X.C., Tian X.F., Tu P.F., Pu X.P. Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease. Eur. J. Pharmacol. 2007, 564:66-74.
7. Koo H.J., Choi M.Y., Im H. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants. Biochem. Biophys. Res. Commun. 2009, 386:165-169.
8. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism inhumans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
9. Lev N., Melamed E., Offen D. Apoptosis and Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:245-250.
10. Liu C.L., Wang J.M., Chu C.Y., Cheng M.T., Tseng T.H. In vivo protective effect of protocatechuic acid on tert-butyl hydroperoxide-induced rat hepatotoxicity. Food Chem. Toxicol. 2002, 40:635-641.
11. Liu G.W., Zhang C.Y., Yin J.J., Li X., Cheng F.R., Li Y.H., Yang H., Uéda K., Chan P., Yu S. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 2009, 454:187-192.
12. Nagatsu T., Sawada M. L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat. Disord. 2009, 15:S3-S8.
13. Nakamura Y., Torikai K., Ohigashi H. Toxic dose of a simple phenolic antioxidant, protocatechuic acid, attenuates the glutathione level in ICR mouse liver and kidney. J. Agric. Food Chem. 2001, 49:5674-5678.
14. Richardson J.R., Caudle W.M., Wang M., Dean E.D., Pennell K.D., Miller G.W. Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease. FASEB J. 2006, 20:1695-1697.
15. Rozas G., Lopez-Martin E., Guerra M.J., Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J. Neurosci. Methods 1998, 83:165-175.
16. Saito S., Kawabata J. Effects of electron-withdrawing substituents on DPPH radical scavenging reactions of protocatechuic acid and its analogues in alcoholic solvents. Tetrahedron 2005, 61:8101-8108.
17. Serra P.A., Pluchino S., Marchetti B., Desole M.S., Miele E. The MPTP mouse model: cues on DA release and neural stem cell restorative role. Parkinsonism Relat. Disord. 2008, 14:S189-S193.
18. Shi G.F., An L.J., Jiang B., Guan S.I., Bao Y.M. Alpinia protocatechuic acid protects against oxidative damage in vitro and reduces oxidative stress in vivo. Neurosci. Lett. 2006, 403:206-210.
19. Singha S., Dikshit M. Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Brain Res. Rev. 2007, 54:233-250.
20. Sun F., Kanthasamy A., Anantharam V., Kanthasamy A.G. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease. Pharmacol. Ther. 2007, 114:327-344.
21. Toulouse A., Sullivan A.M. Progress in Parkinson's disease-where do we stand?. Prog. Neurobiol. 2008, 85:376-392.
22. von Bohlen und Halbach O., Schober A., Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog. Neurobiol. 2004, 73:151-177.
23. Yang Y.X., Wood N.W., Latchman D.S. Molecular basis of Parkinson's disease. NeuroReport 2009, 20:150-156.
24. Zhang H.N., An C.N., Xu M., Guo D.A., Li M., Pu X.P. Protocatechuic acid inhibits rat pheochromocytoma cell damage induced by a dopaminergic neurotoxin. Biol. Pharm. Bull. 2009, 32:1866-1869.